What were the key takeaways from InMode’s earnings call?

What factors drove the changes in InMode's revenue and profit?

What is the market's earnings forecast for InMode next quarter?

What is the revenue and EPS growth rate for InMode year over year?

What does InMode do and what are its main business segments?

What guidance did InMode's management provide for the next earnings period?

What is InMode's gross profit margin?

What is InMode's latest dividend and current dividend yield?

- **Revenue Stabilization**: 2025 revenue down 6% YoY to $370.5M, with encouraging signs in consumables (+22% of revenue) and Europe (+38% Q4 sales)
- **New Product Pipeline**: 2026 launches of pico laser and Morpheus/Erbium combo device expected to drive growth
- **Margin Headwinds**: 2026 gross margin target of 75-77% due to lower-margin laser products
- **Strategic Alternatives**: Board exploring options after $508M share buyback
- **Clinical Pipeline**: Dry eye indication under FDA review with potential 2027 approval

**【CEO Summary Section】**
- Total revenue for 2025 declined 6% YoY to $370.5 million, with Q4 revenue at $103.9 million, up 6% YoY. North America revenue was down 10% YoY, while international sales grew 15% to $171.8 million (46% of total revenue). 
- Encouraging signs of stabilization: consumables/services revenue increased to 22% of total (from 20% in 2024), and Europe saw record Q4 sales (+38% YoY). 
- Strategic initiatives: 
  - Appointed new North America President in Q4 to unify operations
  - Segmented sales force by aesthetic/wellness platforms
  - Launched CO2 laser platform in 2025
  - Planning 2026 launches of Korean-made pico laser and Morpheus/Erbium combo device
- 2026 outlook: Revenue expected to be flat with 2025 (~$370M), with focus on product mix evolution and industry stabilization.

**【CFO Financial Commentary】**
- Q4 2025 GAAP net income: $420M (down 63% YoY due to one-time tax benefit in 2024)
- Non-GAAP EPS: $0.46 vs $0.42 in Q4 2024
- Full year 2025 metrics:
  - Revenue: $370.5M (-6% YoY)
  - Gross margin: 78% (flat YoY)
  - Operating expenses: $205.6M (+0.5% YoY)
  - Free cash flow: $555.3M
- 2026 guidance:
  - Revenue: $365-375M
  - Non-GAAP gross margin: 75-77%
  - Non-GAAP EPS: $1.43-1.48

**【Q&A Highlights】**
- **Strategic Alternatives**: Board exploring strategic alternatives via Bank of America; $508M share buyback since 2023
- **Gross Margin Concerns**: New laser products (CO2, pico) expected to weigh on margins (~75% target vs historical 78-79%)
- **Product Contributions**: 2025 CO2 and ApexRF platforms contributed ~$15M
- **International Expansion**: Added subsidiaries in Austria, Belgium, Ireland; 80% of sales direct through 13 subsidiaries
- **R&D/Sales Spend**: 2026 R&D to increase for women's health clinical trials; marketing spend focused on new products
- **Dry Eye Indication**: FDA protocol under review; potential approval in Q2 2027

InMode Ltd. (INMD) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 2025 consumables/services up 26% YoY, driven by non-US markets.\n- **Leadership Expansion**: New North America President with 10+ years industry tenure.\n- **Pipeline Momentum**: 2026 ophthalmology dry eye study, new aesthetic lasers H1 2026.\n- **Financial Discipline**: 11% YoY opex decline, $532M cash runway.\n- **Market Risk**: 2026 sales cautious amid macro uncertainty.

**【CEO Summary Section】**
- Q3 2025 revenue of $93.2M, up 26% YoY in consumables and services, driven by non-US markets.\n- Launched new subsidiaries in Argentina and Thailand, targeting direct engagement and localized support.\n- Men wellness platform soft launch underway, with commercial rollout expected late 2025.\n- Appointed Michael Dennison as President of North America, leveraging his 10+ years of industry experience.\n- 2026 pipeline includes new aesthetic lasers and urology devices, with R&D focus on noninvasive solutions.\n\n**【CFO Financial Commentary】**
- GAAP net income $21.8M, non-GAAP EPS $0.38 vs. $0.70 YoY.\n- Gross margins 78% (down 400bps YoY due to tariffs).\n- Operating expenses $51.4M (11% YoY decline).\n- Q4 2025 guidance: $365-375M revenue, 78-80% gross margins.\n- Strong balance sheet with $532.3M cash, +$24.5M Q3 cash flow.\n\n**【Q&A Highlights】**
- 2026 sales growth cautious due to lingering macro uncertainty.\n- Interest rate reductions may boost capital equipment sales in 2026.\n- Ophthalmology initiative: FDA protocol discussions, dry eye study Q2 2026.\n- Argentina and Thailand subsidiaries to drive regional expansion.\n- Noninvasive growth driven by new CO2 and men wellness platforms.\n- Q3 2025 disposable tips sales 230,000 units, +15% YoY.

InMode Ltd. (INMD) Q3 2025 Earnings Call Transcript

- **Revenue Resilience**: $95.6 million Q2 revenue, 84% from minimally invasive platforms, with 48% of sales outside the U.S.
- **Cost Management**: Operating expenses up 5% YoY, driven by sales expansion and marketing.
- **Guidance Adjustment**: 2025 revenue lowered to $365-375 million due to macroeconomic headwinds.
- **Tariff Risk**: 10% U.S. import tax could reduce gross margin by 1-1.5% in 2025.
- **Growth Drivers**: Noninvasive platforms (e.g., OptimasMAX) contributed 10%+ of U.S. system sales in Q2, with wellness platform launches in Q4.
- **Balance Sheet Strength**: $510.7 million in cash as of Q2, supporting strategic investments.


**【CEO Summary Section】**
- CEO highlights challenges in North America due to reduced physician spending, leading to slower treatment and capital investment.
- Restructuring efforts include appointing a dedicated sales team for the Envision platform in ophthalmology and expanding direct operations in Thailand and Argentina.
- Launching new wellness platforms for urology (blood circulation, pain relief) in late August, with soft launch revenue in Q2 and expected contributions in Q4.
- Emphasizes long-term confidence in the company's diversified portfolio and balance sheet despite short-term headwinds.

**【CFO Financial Commentary】**
- Q2 2025 revenue: $95.6 million (84% from minimally invasive platforms), with 48% of sales outside the U.S. (record $23 million in Europe).
- Gross margin: 80% (GAAP) and 80% (Non-GAAP), consistent with Q2 2024.
- Operating expenses: $53.6 million (GAAP) and $50.5 million (Non-GAAP), up 5% and 9% YoY due to sales team expansion and marketing.
- Updated 2025 guidance: Revenue $365-375 million (down from $395-405 million), Non-GAAP EPS $1.55-1.59 (down from $1.64-1.68).
- Tariffs: 10% U.S. import tax could reduce gross margin by 2-3% annually.

**【Q&A Key Highlights】**
- **Market Dynamics**: Q1 and Q2 misses attributed to macroeconomic uncertainty; no change in physician or patient behavior observed.
- **Product Performance**: Noninvasive platforms (e.g., OptimasMAX) drove 10%+ of U.S. system sales in Q2, offsetting minimally invasive declines.
- **Tariff Impact**: 10% U.S. tariff on Israeli imports could reduce 2025 gross margin by 1-1.5%.
- **Urology Platform**: Launching for blood circulation and pain relief in Q4, with FDA approval for erectile dysfunction pending.
- **Capital Allocation**: $508 million spent on buybacks since 2023; no immediate plans for acquisitions or dividends.


InMode Ltd. (INMD) Q2 2025 Earnings Call Transcript

- **Revenue decline**: Q1 2025 revenue fell 3% YoY to $77.9 million, with U.S. sales dropping to 50% of total revenue.
- **Tariff impact**: 10% import tariffs expected to reduce gross margins by 2-3%, with potential for higher rates.
- **New product strategy**: Delayed wellness platform launch; existing products (e.g., Ignite) face 25%+ revenue declines.
- **Capital return**: $412 million returned to shareholders over 12 months, but no further buybacks planned.
- **Guidance caution**: 2025 targets ($395-405 million) hinge on Q2 recovery; operating margins expected to decline 4-5%.

**【CEO Summary Section】**
- CEO Moshe Mizrahy highlighted ongoing macroeconomic challenges in the medical aesthetic market, including soft consumer demand and cautious capital investment by providers. Despite this, the company maintained its workforce and committed to innovation, with plans to launch a new wellness platform later in 2025.
- InMode completed a $127 million share repurchase in Q1, part of a $412 million capital return over the past year, representing 27% of total capital.
- The U.S. market faced significant headwinds, with Q1 U.S. sales declining to 50% of total revenue (from 62% in 2024), while international sales in Europe reached a record high.
- The company emphasized its strong balance sheet ($512.9 million in cash as of Q1) and ability to weather the slowdown.

**【CFO Financial Commentary】**
- Q1 2025 revenue was $77.9 million (-3% YoY), with non-GAAP gross margin at 79% (down 1% YoY). Minimally invasive platforms accounted for 87% of revenue, up from 85% in Q1 2024.
- Updated 2025 guidance: revenue $395-405 million (vs. prior $400-410 million), non-GAAP EPS $1.64-1.68 (vs. prior $1.95-1.99). Operating margins expected to decline 4-5% due to U.S. market pressure.
- Tariffs on Israeli imports (currently 10%) are expected to reduce gross margins by 2-3%, with uncertainty around potential rate increases.

**【Q&A Highlights】**
- **Sales Mix & Tariffs**: U.S. market weakness (driven by high leasing rates and consumer caution) offset stronger international performance. Tariffs' 2-3% margin impact is factored into guidance, but price hikes are avoided to maintain competitiveness.
- **Guidance Reiteration**: Q2 performance will determine if 2025 targets are achievable, with Q2 typically 25-26% of annual revenue. If Q2 underperforms, guidance may be revised.
- **Capital Allocation**: Share buybacks paused due to lack of stock price impact; focus on M&A and R&D. Dividends would incur 20% Israeli tax.
- **New Products**: Wellness platform launch delayed until market recovery; existing products (e.g., Ignite, OptimasMax) face similar demand headwinds.


InMode (INMD)-28 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Decline Driven by Macro**: FY24 revenue down 20% to $394.8M, impacted by aesthetic industry headwinds and macroeconomic factors.
- **Gross Margin Resilience**: Maintained 80%+ non-GAAP gross margin, highest in industry.
- **Innovation Pipeline**: 2025 launches of fractional CO2 laser and medical platform position for growth in facial rejuvenation and surgical markets.
- **Shareholder Focus**: Aggressive buyback program (27% of shares in 15 months) and exploring additional capital returns to enhance shareholder value.

**【CEO Key Initiatives】**
- **2024 Innovation Highlights**: Launched IgniteRF and OptimasMAX platforms, featuring advanced RF and multi-application technologies. Despite delayed market entry due to training complexity, early physician feedback is positive.
- **2025 Pipeline Expansion**: Planning to launch fractional CO2 laser and medical platform, targeting facial rejuvenation and surgical markets. Morpheus technology bundling with CO2 laser expected to drive adoption.
- **Shareholder Returns**: Returned $285M to shareholders in 2024 via buybacks (19% of shares). Announced new 10% share repurchase program, bringing total buybacks to 27% of shares over 15 months. Exploring additional capital returns by year-end.

**【CFO Financial Performance】**
- **Q4 2024 Results**: Revenue $97.9M (GAAP), 79% gross margin. Full year 2024 revenue $394.8M (-20% YoY), 81% non-GAAP gross margin.
- **Revenue Mix**: Minimally invasive platforms 86% of Q4 revenue. Consumables/services 20% of annual revenue (+4% YoY).
- **International Performance**: Q4 international sales $35.2M (-23% YoY). Full year international sales $150M (-19% YoY), accounting for 38% of total revenue.
- **Cost Management**: GAAP operating expenses $49.8M (Q4) / $204.5M (FY24), down 10% / 5% YoY. Non-GAAP operating margin 32% (Q4) / 33% (FY24), vs 45% in FY23.

InMode (INMD)-4 Feb 25-2024 Q4 Earnings call transcript

InMode (INMD)-30 Oct 24-2024 Q3 Earnings call transcript

Inmode (INMD)-1 Aug 24-2024 Q2 Earnings call transcript

Inmode (INMD)-2 May 24-2024 Q1 Earnings call transcript

InMode Ltd. (INMD) Q4 2023 Earnings Call Transcript

- **Revenue Record**: Q2 2023 revenue of $136.1M (+20% YoY) driven by 1,600+ platforms and 270,000 disposable units sold.
- **Global Expansion**: New subsidiaries in Japan and Germany to enable direct sales; added to Russell 2000 Index.
- **Product Pipeline**: Four new technologies launching in 12 months, including upgraded Morpheus8 and multi-application platforms.
- **Financial Strength**: $629.4M cash, Non-GAAP EPS of $0.72 (+22% YoY), and 2023 guidance of $530-540M revenue.
- **Q4 Growth Outlook**: Consumable sales expected to surge post-summer slowdown, with Envision platform targeting ophthalmology market.

**【CEO Summary Section】**
- **Record Revenue Growth**: Q2 2023 revenue reached $136.1 million, a 20% year-over-year increase, driven by strong platform and consumable sales. Over 1,600 platforms and 270,000 disposable units were sold, both company records.
- **Global Expansion**: New subsidiaries established in Japan and Germany to enable direct sales. InMode is one of the few companies where founders remain actively involved in management.
- **Product Innovation**: Plans to launch four new technologies in the next 12 months, including upgraded Morpheus8, hands-free platforms, and multi-application devices. Eight FDA studies are currently in process.
- **Market Recognition**: InMode was added to the Russell 2000 Index, reflecting its growth potential as a mid-cap company.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income of $420 million, Non-GAAP EPS of $0.72 (up 22% YoY). Gross margin remained stable at 84% on a GAAP basis.
- **Expense Management**: Sales and marketing expenses increased to $51.1 million (29% YoY) due to direct-to-consumer campaigns and event hosting. Operating expenses totaled $57 million (26% YoY growth).
- **Balance Sheet Strength**: $629.4 million in cash and marketable securities as of Q2 2023.
- **Updated Guidance**: Full-year 2023 revenue projected at $530-540 million, with Non-GAAP EPS expected between $2.62-2.66.

**【Q&A Highlights】**
- **Consumable Sustainability**: Q3 2023 consumable sales remain strong despite seasonal summer slowdowns, driven by Morpheus8 adoption. Q4 is expected to show significant growth.
- **Capital Equipment Trends**: North America and ROW markets show resilience despite high interest rates. Financing strategies include alternative sources and regional leasing partnerships.
- **R&D and Innovation**: Emphasis on product differentiation and clinical validation (e.g., dry eye study for Envision platform). R&D spending is optimized for productivity, not percentage of revenue.
- **Strategic Acquisitions**: Open to M&A opportunities, particularly for IP that enhances product portfolio. Recent acquisition of Viviv IP for women's health procedures.
- **Ophthalmology Expansion**: Envision platform gaining traction in ophthalmology with 44% YoY consumable growth. FDA clearance for dry eye treatment expected by year-end.

Actual				0.075	0.105	0.315	0.47	0.345	0.51	0.55	0.64	0.4	0.59	0.66	0.78	0.52	0.72	0.61	0.71	0.32	0.34	0.7	0.42	0.31	0.47	0.38	0.46
Forecast				0.1624	-0.031	0.2392	0.3372	0.267	0.4328	0.4997	0.5726	0.3633	0.513	0.585	0.6664	0.4679	0.6508	0.6405	0.6568	0.4317	0.3823	0.5666	0.5278	0.3536	0.4111	0.355	0.4168
Surprise	0.00%	0.00%	0.00%	-53.82%	+438.71%	+31.69%	+39.38%	+29.21%	+17.84%	+10.07%	+11.77%	+10.10%	+15.01%	+12.82%	+17.05%	+11.13%	+10.63%	-4.76%	+8.10%	-25.87%	-11.06%	+23.54%	-20.42%	-12.33%	+14.33%	+7.04%	+10.36%

INMD

INMD fundamentals

INMD Q4 2025 Earnings

Earnings Call

You can ask Aime

INMD

INMD fundamentals

INMD Q4 2025 Earnings

Earnings Call

INMD Earnings Call Summary for Q4/20258:30 AM on Feb 10, 2026

INMD Earnings Call Summary for Q3/20258:30 AM on Nov 5, 2025

INMD Earnings Call Summary for Q2/20258:30 AM on Jul 30, 2025

INMD Earnings Call Summary for Q1/20258:30 AM on Apr 28, 2025

INMD Earnings Call Summary for Q4/20248:30 AM on Feb 4, 2025

You can ask Aime